Researchers Find New Drug Treatment for Eye Muscle Condition
Source Newsroom: Association for Research in Vision and Ophthalmology (ARVO)
Newswise — Orlando, Fla. — In another example of serendipity advancing scientific research, investigators have discovered a new class of drugs to treat an eye condition called nystagmus. The research is being presented at the 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Orlando, Fla.
After a patient with nystagmus accidentally sprayed a nerve agent sprayed in his right eye, later reported “seeing better” and that the “nystagmus was gone.” Vision scientists followed up on this finding by applying the nerve agent to the eyes of sheep dogs with an inherited form of nystagmus. The results suggest that the agent is a safe and effective treatment for the condition.
Nystagmus is an eye condition where the eye suffers from involuntary movement, hindering vision. The drug is believed to interact with the nerves of the eye’s surrounding muscles.
Abstract Title: Efficacy and Safety of New Topical Sodium Pump Inhibitor (NSPI) in Reducing Eye Oscillations in A Canine model of Infantile Nystagmus Syndrome (INS)
Presentation Start/End Time: Wednesday, May 7, 11:15am – 11:30am
Location: S 230GH
Session Number: 430
# # #
The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include some 12,000 eye and vision researchers from over 70 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology.
All abstracts accepted for presentation at the ARVO Annual Meeting represent previously unpublished data and conclusions. This research may be proprietary or may have been submitted for journal publication. Embargo policy: Journalists must seek approval from the presenter(s) before reporting data from paper or poster presentations. Press releases or stories on information presented at the ARVO Annual Meeting may not be released or published until the conclusion of the presentation.